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Introduction
It has been reported that genetic background linked to sero-
tonin (5-HT) metabolism is involved in migraine pathogen-
esis. Indeed, the most effective drugs in acute migraine are
the triptans, highly selective 5-HT1B/1D agonists.
There is evidence that 5-HT activity is regulated by a
functional polymorphism within the promoter region of
the 5-HT transporter gene (5-HTT gene-linked promoter
region, 5-HTTLPR) [1]. The 5-HTTLPR provides the pri-
mary mechanism for reuptake of 5-HT after its release
into the synaptic cleft and is thus critical to the mainte-
nance of brain 5-HT homeostasis. In vitro studies evi-
denced that the basal activity of 5-HTTLPR allele with a
44-base pair insertion (long variant, L) leads to nearly
twice as much 5-HTT transcription compared to the other
allele (short variant, S) [2].
Different studies investigated the role of genetic vari-
ations of 5-HT receptors as risk factors for migraine, their
role being still not completely understood [3–5]. A recent
work suggested a link between 5-HTTLPR polymorphism
and migraine with aura [6].
In the current study, we further evaluate the role of
functional 5-HTTLPR polymorphism as a risk factor for
migraine.
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Abstract In the present work, we
report that the functional serotonin
transporter gene promoter (5-
HTTLPR) polymorphism is
involved in migraine pathogenesis.
The distribution of 5-HTTLPR
genotypes was significantly differ-
ent in MA patients (S/S vs. S/L vs.
L/L=32.7 vs. 42.3 vs. 25.0%), MO
patients (18.5 vs. 39.1 vs. 42.4%)
and CON (18.0 vs. 51.3 vs. 30.7%;
chi-square test, p<0.05). In 5-
HTTLPR S/S carriers, the odds
ratio for MA risk was 2.60 (95%
confidence interval
[95%CI]=1.75–3.85) compared to
CON, and it was 2.14
(95%CI=1.42–3.21) compared to
MO. These data provide a further
insight on the complex genotype-
phenotype relationship involved in
MA pathogenesis, and might even-
tually result in new and individu-
alised prognostic and therapeutic
measures.
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One hundred and forty-four consecutive migraine patients and
105 nonheadache unrelated healthy volunteers were enrolled at
Headache Centres of University of Brescia and “Città di
Brescia” Hospital. All migraine patients and healthy controls
were interviewed by an experienced neurologist. A standardised
record of all demographic characteristics, family history for
migraine, cerebrovascular disease, cardiovascular disease and
neurological disorders was obtained. The presence of other
comorbidities was also evaluated.
All subjects performed a clinical and neurological work-up,
and a blood drawing for 5-HTTLPR genotyping.
The migraine patients were diagnosed as having migraine
without aura (MO) or migraine with aura (MA) according to the
International Headache Society (IHS) criteria [7].
The study was conducted in accordance with local clinical
research regulations and informed consent was required from all
the subjects.
Polymorphism analyses were performed blinded to diagnosis
and genotype.
5-HTTLPR genotyping
Genomic DNA was prepared from 10 ml of blood using the salt-
ing out method. Primers 5’-GGCGTTGCCGCTCTGAATGC-3’
and 5’-GAGGGACTGAGCTGG ACAACC-3’ were used to
assess GC-rich regions composed of 20–23 base pair (bp) repeat-
ing units in the 5-HTTPR gene.
The 50-µl reactions contained 50 nmol genomic DNA, 0.17
mmol/l each of dATP, dCTP and dTTP; 0.083 mmol/l of dGTP;
1.5 mmol/l MgCl2, 0.1 µg of each primer, and 1 unit Taq poly-
merase. Following an initial denaturation step at 95°C for 3
min, DNA was amplified in 35 PCR cycles (95°C for 45 s; 66°C
for 1 min; 72°C for 1 min); the final extension step was 72°C
for 7 min.
A 15-µl aliquot of PCR product was resolved on 2.5%
agarose gel, and genotype was determined by fragments’ size of
484 bp (short allele, S) or 528 bp (long allele, L).
Statistical analysis
The Hardy-Weinberg equilibrium was verified for all tested pop-
ulations. The differences in genotype frequencies and other risk
factors were analysed by the χ2 test. Demographic characteris-
tics in the groups were compared by Student’s t-test or one-way
ANOVA and Bonferroni post-hoc analysis. Odds ratio (OR) and
95% confidence intervals (95% CI) were also calculated. Results
were expressed as mean±standard deviation (SD). The level of
significance was taken at p<0.05.
Results
One hundred and forty-four migraine patients and 105
non-headache migraine subjects were enrolled. Migraine
patients were classified into two subgroups according to
the presence (MA, n=52) or the absence (MO, n=92) of
Table 1 Demographic and clinical characteristics of migraine patients according to migraine subtypes and of nonheadache controls
Variable CON MO MA p*
n 105 92 52 –
Age, years 37.3±7.7 35.1±11.8 33.3±9.9 n.s.
Gender, F% 79.4 80.2 78.8 –
Age at onset, years – 20.0±9.8 21.0±9.5 –
FH migraine, % 8.7 75 77.8 0.0001
FH cerebrovascular disease, % 15.0 39.3 22.5 0.001
FH cardiovascular disease, % 22.3 40.4 22.5 0.02
FH neurological disease, % 9.5 8.3 2.5 n.s.
Smoking, % 18.8 25.8 19.6 n.s.
Hypertension, % 2.3 8.4 6.2 n.s.
Cardiomyopathy, % 1.6 1.2 12.5 0.001
Hypercholesterolaemia, % 0.0 21.4 19.2 0.0001
Dismetabolism, % 1.6 3.6 2.0 n.s.
Asthma, % 3.9 6.0 6.2 n.s.
Allergy, % 9.4 26.5 23.0 0.01
Head trauma, % 5.5 8.4 18.8 0.05
Epilepsy, % 1.5 1.2 4.1 n.s.
Gastritis/gastric disease, % 3.9 27.1 14.6 0.0001
CON, nonheadache unrelated healthy volunteers; MO, migraine patients without aura; MA, migraine patients with aura; F, female; FH,
family history
*Controls vs. MO vs. MA
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aura. MA and MO subgroups did not differ for demo-
graphic characteristics, family history of migraine or other
associated comorbidities.
Patients with migraine showed an increased incidence
of allergies, previous head trauma, hypercholestero-
laemia, gastritis or gastric disease, and cardiomyopathy
compared to the control sample. Family history of
migraine was more common in migraine patients than in
nonheadache volunteers.
The distribution of 5-HTTLPR genotypes was signifi-
cantly different in MA patients (S/S vs. S/L vs. L/L=32.7
vs. 42.3 vs. 25.0%), MO patients (18.5 vs. 39.1 vs. 42.4%)
and CON (18.0 vs. 51.3 vs. 30.7%; chi-square test,
p<0.05).
5-HTTLPR S/S was found to be associated with MA,
its incidence being higher in this group (32.7%) compared
to CON (18.0%, chi-square test, p<0.05) and to MO
patients (18.5%, p<0.05). No difference in demographic
characteristics, i.e., gender or age at onset, family history
of migraine and other associated comorbidities between 5-
HTTLPR S/S and 5-HTTLPR non-S/S carriers was
observed.
In 5-HTTLPR S/S carriers, the OR for MA risk was
2.60 (95%CI=1.75–3.85) compared to CON, and it was
2.14 (95%CI=1.42–3.21) compared to MO.
Discussion
The relationship between the 5-HT pathway and migraine is
well established. Thus, different studies have investigated a
possible link between genetic background linked to 5-HT
metabolism and migraine pathogenesis. It has been suggested
that T102C polymorphism of 5-HT2A gene is a risk factor for
migraine [3], and a recent work has supported the view that 5-
HTTLPR genetic variation is related to migraine with aura [6].
Our results confirm and extend previous studies, and
may have several implications for clinical practice. These
data suggest that MA and MO have distinct genetic pre-
disposing factors. Moreover, the well known role of this
polymorphism on 5-HT transcription [2] may reflect a dif-
ferent response to 5-HT agonist drugs, such as triptans,
whose migraine symptomatic effect is still unpredictable.
Further studies are required to elucidate the role of 5-
HTTLPR polymorphism in migraine. Notwithstanding,
these data provide a further insight on the complex geno-
type-phenotype relationship involved in migraine patho-
genesis, and might eventually result in new and individu-
alised prognostic and therapeutic measures.
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